Hisateru Komatsu
Papers
4
Total Citations
28
H-Index
3
About
Hisateru Komatsu is a leading surgical oncologist whose research focuses on advanced gastric and rectal cancers, with particular emphasis on minimally invasive surgical techniques and novel chemotherapeutic strategies. His major contributions span two critical domains: the clinical management of claudin-18 isoform 2 (CLDN18.2)-positive gastric cancer and the optimization of robotic surgery for gastrointestinal malignancies. In landmark work, Komatsu documented the first real-world cases of protein-losing enteropathy induced by zolbetuximab, the targeted therapy now central to treating HER2-negative, CLDN18.2-positive advanced gastric cancer—a finding that has garnered 13 citations and carries significant implications for patient safety. He has also advanced the field of robotic gastrectomy, demonstrating comparable perioperative outcomes and three-year survival between robotic and laparoscopic approaches (10 citations). Notably, his pioneering learning curve analysis for prophylactic bilateral robot-assisted lateral lymph node dissection in lower rectal cancer provides essential benchmarks for surgical training and adoption. Through these contributions—spanning adverse event characterization, comparative effectiveness research, and surgical education—Komatsu is shaping both the safety and precision of contemporary oncologic surgery.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4